Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community

In persons selected from a population-based study, elevated amyloid levels at baseline were associated with worse cognition and imaging biomarkers at baseline and with greater clinical decline and neurodegeneration. These results have implications for the design of randomized clinical trials for AD.